References
1. Chen T, Wang Y, Goetz L, et al. Novel fusion sarcomas including targetable NTRK and ALK. Ann Diagn Pathol . 2021;54(July 2021):1-12. doi:10.1016/j.anndiagpath.2021.151800
2. Davis JL, Al-Ibraheemi A, Rudzinski ER, Surrey LF. Mesenchymal neoplasms with NTRK and other kinase gene alterations.Histopathology . 2022;80(1):4-18. doi:10.1111/his.14443
3. Foster JH, Voss SD, Hall D, et al. Activity of Crizotinib in Patients with ALK-aberrant Relapsed/Refractory Neuroblastoma: A Children’s Oncology Group Study (ADVL0912). Clin Cancer Res . 2021;27(13):3543-3548. doi:10.1158/1078-0432.CCR-20-4224.
4. Wu J, Hu Y, Abdihamid O, Huang G, Xiao S, Li B. Crizotinib in Sarcomatous Malignancies Harboring ALK Fusion With a Definitive Partner(s): Response and Efficacy. Front Oncol . 2021;11(October):1-9. doi:10.3389/fonc.2021.684865
5. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature . 2007;448(7153):561-566. doi:10.1038/nature05945
6. Crystal AS, Shaw AT. New targets in advanced NSCLC: EML4-ALK.Clin Adv Hematol Oncol . 2011;9(3):207-214.
7. Shaw AT, Yeap BY, Solomon BJ, et al. Eff ect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet . 2011;12:1004-1012.
8. Shaw AT, Solomon BJ, Mino-Knudson M. Crizotinib and Testing for ALK.JNCCN . 2011;9(12):1335-1341.
9. Chabner BA. Early Accelerated Approval for Highly Targeted Cancer Drugs. N Engl J Med . 2011;364(12):1087-1089. doi:10.1056/nejmp1100548
10. Nwizu T, Kanteti R, Kawada I, Rolle C, Vokes EE, Salgia R. Crizotinib (PF02341066) as a ALK /MET inhibitor— Special Emphasis as a Therapeutic Drug Against Lung Cancer. Drugs Futur . 2011;36(2):91-99. doi:10.1358/dof.2011.036.02.1584112
11. Baranov E, Winsnes K, O’Brien M, et al. Histologic characterization of paediatric mesenchymal neoplasms treated with kinase-targeted therapy. Histopathology . 2022;81(2):215-227. doi:10.1111/his.14680
12. Knezevich SR, McFadden DE, Tao W, Lim JF, Sorensen PHB. A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma. Nat Genet . 1998;18:184-187.
13. Rubin BP, Chen CJ, Morgan TW, et al. Congenital mesoblastic nephroma t(12;15) is associated with ETV6-NTRK3 gene fusion: Cytogenetic and molecular relationship to congenital (infantile) fibrosarcoma. Am J Pathol . 1998;153(5):1451-1458. doi:10.1016/S0002-9440(10)65732-X
14. Suurmeijer AJ, Antonescu CR. World Health Organization Classification of Soft Tissue and Bone Tumours . 5th ed. (Fletcher D, ed.). IARC Press; 2020. doi:978-92-832-4502-5
15. Kao YC, Suurmeijer AJH, Argani P, et al. Soft tissue tumors characterized by a wide spectrum of kinase fusions share a lipofibromatosis-like neural tumor pattern. Genes Chromosom Cancer . 2020;59(10):575-583. doi:10.1002/gcc.22877
16. Abs D, Landman S, Osio A, et al. Spindle cell tumor with CD34 and S100 co-expression and distinctive stromal and perivascular hyalinization showing EML4-ALK fusion. J Cutan Pathol . 2021;48(7):896-901. doi:10.1111/cup.13926
17. Lopez-Nunez O, Surrey LF, Alaggio R, Fritchie KJ, John I. Novel PPP1CB-ALK fusion in spindle cell tumor defined by S100 and CD34 coexpression and distinctive stromal and perivascular hyalinization.Genes Chromosom Cancer . 2020;59(8):495-499. doi:10.1002/gcc.22844
18. Dermawan JK, Azzato EM, Goldblum JR, Rubin BP, Billings SD, Ko JS. Superficial ALK-rearranged myxoid spindle cell neoplasm: a cutaneous soft tissue tumor with distinctive morphology and immunophenotypic profile. Mod Pathol . 2021;34(9):1710-1718. doi:10.1038/s41379-021-00830-w
19. Dermawan JK, DiNapoli SE, Mullaney KA, et al. ALK-rearranged Mesenchymal Neoplasms: A Report of 9 cases Further Expanding the Clinicopathologic Spectrum of Emerging Kinase Fusion Positive Group of Tumors. Genes Chromosom Cancer . 2022;62(2):75-84.